Mendra launches with $82M Series A to build AI-driven Rare Disease Therapeutics Platform

San Francisco, CA, January 22, 2026 (Business Wire) -- Mendra launched with an oversubscribed $82 million Series A financing to acquire, develop, and commercialize therapies for rare diseases with high unmet need. The round was co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC. The company plans to leverage artificial intelligence to accelerate patient identification, clinical trial enrollment, and global commercialization as it builds an initial portfolio of rare disease assets.

Read full article here.